Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Multimodal imaging guides surgical management in a preclinical spinal implant infection model.

Zoller SD, Park HY, Olafsen T, Zamilpa C, Burke ZD, Blumstein G, Sheppard WL, Hamad CD, Hori KR, Tseng JC, Czupryna J, McMannus C, Lee JT, Bispo M, Romero Pastrana F, Raineri EJ, Miller JF, Miller LS, van Dijl JM, Francis KP, Bernthal NM.

JCI Insight. 2019 Feb 7;4(3). pii: 124813. doi: 10.1172/jci.insight.124813. [Epub ahead of print]

2.

Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.

D'Souza JW, Hensley H, Doss M, Beigarten C, Torgov M, Olafsen T, Yu JQ, Robinson MK.

J Nucl Med. 2017 Jan;58(1):175-180. doi: 10.2967/jnumed.116.178780. Epub 2016 Aug 18.

3.

Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies.

Tavaré R, McCracken MN, Zettlitz KA, Salazar FB, Olafsen T, Witte ON, Wu AM.

J Nucl Med. 2015 Aug;56(8):1258-64. doi: 10.2967/jnumed.114.153338. Epub 2015 May 7.

4.

Characterization of a double-sided silicon strip detector autoradiography system.

Örbom A, Ahlstedt J, Serén T, Auterinen I, Kotiluoto P, Hauge H, Östlund K, Olafsen T, Wu AM, Dahlbom M, Strand SE.

Med Phys. 2015 Feb;42(2):575-84. doi: 10.1118/1.4905049.

PMID:
25652478
5.

Numerical comparison of iodine-based and indium-based antibody biodistributions.

Williams LE, Wu AM, Kenanova VE, Olafsen T, Yazaki PJ.

Cancer Biother Radiopharm. 2014 Apr;29(3):91-8. doi: 10.1089/cbr.2013.1564. Epub 2014 Jan 20.

PMID:
24443889
6.

Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo.

Tavaré R, McCracken MN, Zettlitz KA, Knowles SM, Salazar FB, Olafsen T, Witte ON, Wu AM.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1108-13. doi: 10.1073/pnas.1316922111. Epub 2014 Jan 3.

7.

Levels of murine, but not human, CXCL13 are greatly elevated in NOD-SCID mice bearing the AIDS-associated Burkitt lymphoma cell line, 2F7.

Widney DP, Olafsen T, Wu AM, Kitchen CM, Said JW, Smith JB, Peña G, Magpantay LI, Penichet ML, Martinez-Maza O.

PLoS One. 2013 Aug 2;8(8):e72414. doi: 10.1371/journal.pone.0072414. Print 2013.

8.

Fc engineering: serum half-life modulation through FcRn binding.

Olafsen T.

Methods Mol Biol. 2012;907:537-56. doi: 10.1007/978-1-61779-974-7_31.

PMID:
22907373
9.

Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments.

Fu M, Brewer S, Olafsen T, Wu AM, Gordon LK, Said J, Braun J, Wadehra M.

Mol Imaging Biol. 2013 Feb;15(1):68-78. doi: 10.1007/s11307-012-0558-y.

10.

Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life.

Andersen JT, Foss S, Kenanova VE, Olafsen T, Leikfoss IS, Roopenian DC, Wu AM, Sandlie I.

J Biol Chem. 2012 Jun 29;287(27):22927-37. doi: 10.1074/jbc.M112.355131. Epub 2012 May 8.

11.

ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging.

Olafsen T, Sirk SJ, Olma S, Shen CK, Wu AM.

Tumour Biol. 2012 Jun;33(3):669-77. doi: 10.1007/s13277-012-0365-8. Epub 2012 Mar 6.

PMID:
22392499
12.

Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment.

Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS.

EJNMMI Res. 2011 Nov 7;1(1):24. doi: 10.1186/2191-219X-1-24.

13.

Protein targeting constructs in alpha therapy.

Olafsen T, Elgqvist J, Wu AM.

Curr Radiopharm. 2011 Jul;4(3):197-213. Review.

PMID:
22201709
14.

CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer.

Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS.

Int J Mol Imaging. 2011;2011:834515. doi: 10.1155/2011/834515. Epub 2011 Sep 6.

15.

Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer.

Girgis MD, Kenanova V, Olafsen T, McCabe KE, Wu AM, Tomlinson JS.

J Surg Res. 2011 Oct;170(2):169-78. doi: 10.1016/j.jss.2011.03.065. Epub 2011 Apr 20.

PMID:
21601881
16.

The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry.

Morizono K, Xie Y, Olafsen T, Lee B, Dasgupta A, Wu AM, Chen IS.

Cell Host Microbe. 2011 Apr 21;9(4):286-98. doi: 10.1016/j.chom.2011.03.012.

17.

Unexpected expression pattern for glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) in mouse tissues revealed by positron emission tomography scanning.

Olafsen T, Young SG, Davies BS, Beigneux AP, Kenanova VE, Voss C, Young G, Wong KP, Barnes RH 2nd, Tu Y, Weinstein MM, Nobumori C, Huang SC, Goldberg IJ, Bensadoun A, Wu AM, Fong LG.

J Biol Chem. 2010 Dec 10;285(50):39239-48. doi: 10.1074/jbc.M110.171041. Epub 2010 Sep 30.

18.

Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins.

Kenanova VE, Olafsen T, Salazar FB, Williams LE, Knowles S, Wu AM.

Protein Eng Des Sel. 2010 Oct;23(10):789-98. doi: 10.1093/protein/gzq054. Epub 2010 Aug 28.

19.

Evaluation of two internalizing carcinoembryonic antigen reporter genes for molecular imaging.

Barat B, Kenanova VE, Olafsen T, Wu AM.

Mol Imaging Biol. 2011 Jun;13(3):526-535. doi: 10.1007/s11307-010-0375-0.

20.

An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.

Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1529-38. doi: 10.1007/s00259-010-1433-1. Epub 2010 Apr 1.

21.

Antibody vectors for imaging.

Olafsen T, Wu AM.

Semin Nucl Med. 2010 May;40(3):167-81. doi: 10.1053/j.semnuclmed.2009.12.005. Review.

22.

ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies).

Olafsen T, Sirk SJ, Betting DJ, Kenanova VE, Bauer KB, Ladno W, Raubitschek AA, Timmerman JM, Wu AM.

Protein Eng Des Sel. 2010 Apr;23(4):243-9. doi: 10.1093/protein/gzp081. Epub 2010 Jan 6.

23.

Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT.

Afshar S, Olafsen T, Wu AM, Morrison SL.

J Exp Clin Cancer Res. 2009 Dec 3;28:147. doi: 10.1186/1756-9966-28-147.

24.

Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.

Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, Raubitschek AA, Timmerman JM, Wu AM.

J Nucl Med. 2009 Sep;50(9):1500-8. doi: 10.2967/jnumed.108.060426. Epub 2009 Aug 18.

25.

Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.

Vaidyanathan G, Jestin E, Olafsen T, Wu AM, Zalutsky MR.

Nucl Med Biol. 2009 Aug;36(6):671-80. doi: 10.1016/j.nucmedbio.2009.04.002.

26.

Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection.

Barat B, Sirk SJ, McCabe KE, Li J, Lepin EJ, Remenyi R, Koh AL, Olafsen T, Gambhir SS, Weiss S, Wu AM.

Bioconjug Chem. 2009 Aug 19;20(8):1474-81. doi: 10.1021/bc800421f. Epub 2009 Jul 31.

27.

Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2.

Sirk SJ, Olafsen T, Barat B, Bauer KB, Wu AM.

Bioconjug Chem. 2008 Dec;19(12):2527-34. doi: 10.1021/bc800113v.

28.

Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors.

Leyton JV, Olafsen T, Lepin EJ, Hahm S, Bauer KB, Reiter RE, Wu AM.

Clin Cancer Res. 2008 Nov 15;14(22):7488-96. doi: 10.1158/1078-0432.CCR-07-5093.

29.

Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors.

Leyton JV, Olafsen T, Sherman MA, Bauer KB, Aghajanian P, Reiter RE, Wu AM.

Protein Eng Des Sel. 2009 Mar;22(3):209-16. doi: 10.1093/protein/gzn055. Epub 2008 Oct 28.

30.

Engineered antibody fragments with infinite affinity as reporter genes for PET imaging.

Wei LH, Olafsen T, Radu C, Hildebrandt IJ, McCoy MR, Phelps ME, Meares C, Wu AM, Czernin J, Weber WA.

J Nucl Med. 2008 Nov;49(11):1828-35. doi: 10.2967/jnumed.108.054452. Epub 2008 Oct 16.

31.

The pursuit of a scalable nanofabrication platform for use in material and life science applications.

Gratton SE, Williams SS, Napier ME, Pohlhaus PD, Zhou Z, Wiles KB, Maynor BW, Shen C, Olafsen T, Samulski ET, Desimone JM.

Acc Chem Res. 2008 Dec;41(12):1685-95. doi: 10.1021/ar8000348.

32.

Recombinant carcinoembryonic antigen as a reporter gene for molecular imaging.

Kenanova V, Barat B, Olafsen T, Chatziioannou A, Herschman HR, Braun J, Wu AM.

Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):104-14. doi: 10.1007/s00259-008-0921-z. Epub 2008 Aug 22.

33.

Antibodies for molecular imaging of cancer.

Wu AM, Olafsen T.

Cancer J. 2008 May-Jun;14(3):191-7. doi: 10.1097/PPO.0b013e31817b07ae. Review.

PMID:
18536559
34.

Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging.

Venisnik KM, Olafsen T, Gambhir SS, Wu AM.

Mol Imaging Biol. 2007 Sep-Oct;9(5):267-77.

PMID:
17577599
35.
36.

Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody.

Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE.

J Immunother. 2007 May-Jun;30(4):396-405.

PMID:
17457214
37.

PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.

Cai W, Olafsen T, Zhang X, Cao Q, Gambhir SS, Williams LE, Wu AM, Chen X.

J Nucl Med. 2007 Feb;48(2):304-10.

38.

Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.

Kenanova V, Olafsen T, Williams LE, Ruel NH, Longmate J, Yazaki PJ, Shively JE, Colcher D, Raubitschek AA, Wu AM.

Cancer Res. 2007 Jan 15;67(2):718-26.

39.

Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors.

Venisnik KM, Olafsen T, Loening AM, Iyer M, Gambhir SS, Wu AM.

Protein Eng Des Sel. 2006 Oct;19(10):453-60. Epub 2006 Jul 31.

PMID:
16882674
40.

Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.

Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS, Williams LE, Wong JY, Raubitschek AA, Shively JE, Wu AM.

Cancer Res. 2005 Jul 1;65(13):5907-16.

41.

Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.

Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM.

Cancer Res. 2005 Jan 15;65(2):622-31.

42.

Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting.

Olafsen T, Tan GJ, Cheung CW, Yazaki PJ, Park JM, Shively JE, Williams LE, Raubitschek AA, Press MF, Wu AM.

Protein Eng Des Sel. 2004 Apr;17(4):315-23. Epub 2004 Jun 8.

PMID:
15187222
43.

Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications.

Olafsen T, Cheung CW, Yazaki PJ, Li L, Sundaresan G, Gambhir SS, Sherman MA, Williams LE, Shively JE, Raubitschek AA, Wu AM.

Protein Eng Des Sel. 2004 Jan;17(1):21-7.

44.
45.

Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange.

Wu AM, Tan GJ, Sherman MA, Clarke P, Olafsen T, Forman SJ, Raubitschek AA.

Protein Eng. 2001 Dec;14(12):1025-33.

PMID:
11809933
46.

Cytotoxicity of Antiosteosarcoma Recombinant Immunotoxins Composed of TP-3 Fv Fragments and a Truncated Pseudomonas Exotoxin A.

Onda M, Olafsen T, Tsutsumi Y, Bruland ØS ØS, Pastan I.

J Immunother (1991). 2001 Mar;24(2):144-150.

PMID:
11449071
47.

Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A.

Onda M, Olafsen T, Tsutsumi Y, Bruland OS, Pastan I.

J Immunother. 2001 Mar-Apr;24(2):144-50.

PMID:
11265772
48.

Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activation in vitro.

Choi I, De Ines C, Kürschner T, Cochlovius B, Sörensen V, Olafsen T, Sandlie I, Little M.

Eur J Immunol. 2001 Jan;31(1):94-106.

49.

Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies.

Olafsen T, Munthe Lund CK, Bruland OS, Sandlie I, Michaelsen TE.

Cancer Immunol Immunother. 1999 Oct;48(7):411-8.

PMID:
10501855
50.

IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells.

Olafsen T, Rasmussen IB, Norderhaug L, Bruland OS, Sandlie I.

Immunotechnology. 1998 Oct;4(2):141-53.

PMID:
9853955

Supplemental Content

Loading ...
Support Center